Media formats available:
Recommended
- Lessons from Landmark trials with PCSK9iIdentifying patients for PCSK9 therapy
Kees Hovingh, MD
- Lessons from Landmark trials with PCSK9iGuidelines and the role of non-statin therapies for high risk ASCVD patients
Wouter Jukema, MD
- Lessons from Landmark trials with PCSK9iLandmark trials with PCSK9 inhibitors
Ph. Gabriel Steg, MD